

Arcellx Appoints Olivia Ware To Board Of Directors



Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management.

"On behalf of our entire Board, I'd like to thank Rusty for his many contributions to Arcellx as both a private and publicly traded biotech company. I've personally appreciated Rusty's leadership and guidance and wish him all the best as he focuses on building his new company," said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. "Olivia's deep industry and commercialization expertise will be an invaluable addition to the existing depth of experience on our Board. Olivia was an instrumental player for the launch of several of the world's largest revenue producing oncology drugs, including Rituxan®, Herceptin®, and Avastin®. This experience will allow her to provide strategic guidance as we plan to initiate a Phase 2 pivotal study for our CART-ddBCMA program for the treatment of patients with relapsed or refractory multiple myeloma and focus on delivering our novel cell therapy to patients as quickly as possible. We are excited to welcome someone of Olivia's caliber to our Board and look forward to her contributions as we advance our novel platform through the clinic and maximize the value of our D-Domain technology."

"This is an exciting time to join the Arcellx Board. Arcellx's lead product candidate, CART-ddBCMA, has the potential to be a meaningful treatment option for patients diagnosed with multiple myeloma, an incurable disease," said Olivia Ware. "My passion and track record launching and building blockbuster drug franchises comes from my dedication to serving the needs of patients, their families, and the physicians who treat them. I look forward to serving on the Board and providing my drug development and commercialization expertise as the company continues to progress its lead product candidate and development pipeline in support of its mission of reimagining cell therapy."

Most recently, Ms. Ware served as Senior Vice President, BTK Franchise at Principia Biopharma which was acquired by Sanofi in 2020. Prior to that, she was the Senior Vice President for commercial activities at Proteus Digital Health, Inc., a marketing and strategy consultant, and Chief Commercial Officer at CytRx Corporation. Ms. Ware served in a variety of roles of increasing responsibility at Genentech in sales and marketing, managed care, and leading global cross-functional teams. She currently serves on the public boards of Revance Therapeutics, Inc. and Ambrx, Inc. Ms. Ware holds an M.B.A. in Finance and Marketing from the University of North Carolina, Chapel Hill, and an A.B. from Davidson College.

Ms. Ware replaces Lewis T. "Rusty" Williams, M.D., co-founder, chairman and chief executive officer of Walking Fish Therapeutics, who has served on Arcellx's Board of Directors since 2019.

"It has been an amazing opportunity to be part of Arcellx's growth as it transitioned from a preclinical, private company to a late-stage publicly traded company," said Dr. Williams. "I look forward to following Arcellx's progress as they continue their path toward helping patients."

Source: [Arcellx](#)

Published on : Mon, 16 May 2022